Internal medicine review

Hidradenitis Suppurativa: A Systemic Disease

Sarah Engelhart, Mital Patel, Mital Patel

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the skin. It is characterized by painful draining nodules, abscesses and sinus tracts. It most commonly affects the skin with a high density of apocrine glands including the axilla, inframammary region, inguinal folds, perineum, and buttocks. There is a growing body of evidence that HS is associated with an increased incidence of many systemic comorbidities compared to the general population. HS has been linked to obesity, metabolic syndrome, cardiovascular disease, endocrine disorders, autoimmune disorders, malignancy and psychiatric disorders. In this paper, we reviewed the literature on systemic comorbidities. The strongest evidence exists supporting an association between HS and metabolic syndrome, smoking and cardiovascular disease and moderately strong evidence of an association between HS and inflammatory bowel disease and inflammatory arthropathies. The literature on the skin cancer and endocrine disorders in HS is mixed, and highlights topics that merit further research. Lastly, the literature indicates that HS patients suffer from decreased quality of life, and increased rates of depression and anxiety. While the understanding of HS and its systemic co-morbidities is still in its early stages, we feel that sufficient evidence exists to support a multidisciplinary approach in the treatment of HS patients.

Keywords

Hidradenitis Suppurativa, Chronic inflammatory disease, metabolic syndrome, obesity,

Full Text:

PDF

References

Schlapbach, C., Hanni, T., Yawalkar, N., & Hunger, R. E. (2011). Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol, 65(4), 790-798.

Melnik, B. C., & Zouboulis, C. C. (2013). Potential role of FoxO1 and mTORC1 in the pathogenesis of Western diet-induced acne. Exp Dermatol, 22(5), 311-315.

Van der Zee, H. H., de Ruiter, L., van den Broecke, D. G., Dik, W. A., Laman, J. D., & Prens, E. P. (2011b). Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol., 164(6), 1292-1298.

Shlyankevich, J., Chen, A. J., Kim, G. E., & Kimball, A. B. (2014). Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol, 71(6), 1144-1150.

Kohorst, J. J., Kimball, A. B., & Davis, M. D. (2015). Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol, 73(5 Suppl 1), S27-35.

Tzellos, T., Zouboulis, C. C., Gulliver, W., Cohen, A. D., Wolkenstein, P., & Jemec, G. B. (2015). Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol, 173(5), 1142-1155. doi:10.1111/bjd.14024

Gold, D. A., Reeder, V. J., Mahan, M. G., & Hamzavi, I. H. (2014). The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol, 70(4), 699-703.

Sabat, R., Chanwangpong, A., Schneider-Burrus, S., Metternich, D., Kokolakis, G., Kurek, A., . . . Sterry, W. (2012). Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One, 7(2), e31810.

Shalom, G., Freud, T., Harman-Boehm, I., Polishchuk, I., & Cohen, A. D. (2015). Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol, 173(2), 464-470.

Miller, I. M., Ellervik, C., Vinding, G. R., Zarchi, K., Ibler, K. S., Knudsen, K. M., & Jemec, G. B. (2014). Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol, 150(12), 1273-1280.

Revuz, J. E., Canoui-Poitrine, F., Wolkenstein, P., Viallette, C., Gabison, G., Pouget, F., Bastuji-Garin, S. (2008). Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol, 59(4), 596-601.

Cohen, A. D., Sherf, M., Vidavsky, L., Vardy, D. A., Shapiro, J., & Meyerovitch, J. (2008). Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology, 216(2), 152-155.

Shapiro, J., Cohen, A. D., David, M., Hodak, E., Chodik, G., Viner, A., . . . Heymann, A. (2007). The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol, 56(4), 629-634.

Gisondi, P., Tessari, G., Conti, A., Piaserico, S., Schianchi, S., Peserico, A., Girolomoni, G. (2007). Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol, 157(1), 68-73.

Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006). Risk of myocardial infarction in patients with psoriasis. JAMA, 296(14), 1735-1741.

Vazquez, B. G., Alikhan, A., Weaver, A. L., Wetter, D. A., & Davis, M. D. (2013). Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol, 133(1), 97-103.

Sartorius, K., Emtestam, L., Jemec, G. B., & Lapins, J. (2009). Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol, 161(4), 831-839.

Crowley, J. J., Meekes, J. R., Zouboulis, C. C., Schienfeld, N., Kimball, A. B., Sundaram, M., . . . Kerdel, F. (2014). Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities. Br J Dermatol, 171(6), 1561-1565.

Schrader, A. M., Deckers, I. E., van der Zee, H. H., Boer, J., & Prens, E. P. (2014). Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol, 71(3), 460-467.

Canoui-Poitrine, F., Revuz, J. E., Wolkenstein, P., Viallette, C., Gabison, G., Pouget, F., . . . Bastuji-Garin, S. (2009). Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol, 61(1), 51-57.

Kromann, C. B., Ibler, K. S., Kristiansen, V. B., & Jemec, G. B. (2014). The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol, 94(5), 553-557.

Kromann, C. B., Deckers, I. E., Esmann, S., Boer, J., Prens, E. P., & Jemec, G. B. (2014). Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol, 171(4), 819-824.

Barth, J. H., Layton, A. M., & Cunliffe, W. J. (1996). Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. British Journal of Dermatology, 134, 1057-1059.

Kamal, N., Cohen, B. L., Buche, S., Delaporte, E., & Colombel, J. F. (2016). Features of Patients With Crohn's Disease and Hidradenitis Suppurativa. Clin Gastroenterol Hepatol, 14(1), 71-79.

Miller, I. M., McAndrew, R. J., & Hamzavi, I. (2016). Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa. Dermatol Clin, 34(1), 7-16.

Gonzalez-Lopez, M. A., Hernandez, J. L., Lacalle, M., Mata, C., Lopez-Escobar, M., Lopez-Mejias, R., Blanco, R. (2016). Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol.

Matusiak, L., Beieniek, A., & Szepietowski, J. C. (2009). Hidradenitis suppurativa and associated factors: Still unsolved problems. J Am Acad Dermatol, 61(2), 362-365.

Ring, H. C., & Emtestam, L. (2016). The Microbiology of Hidradenitis Suppurativa. Dermatol Clin, 34(1), 29-35.

Prens, E., & Deckers, I. (2015). Pathophysiology of hidradenitis suppurativa: An update. J Am Acad Dermatol, 73(5 Suppl 1), S8-11.

Jemec, G. B. (2012). Hidradenitis Suppurativa. N Engl J Med, 366, 158-164.

Alikhan, A., Lynch, P. J., & Eisen, D. B. (2009). Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol, 60(4), 539-561.

Egeberg, A., Gislason, G. H., & Hansen, P. R. (2016). Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa. JAMA Dermatol, 152(4), 429-434.

Ahlehoff, O., Gislason, G. H., Charlot, M., Jorgensen, C. H., Lindhardsen, J., Olesen, J. B., Hansen, P. R. (2011). Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med, 270(2), 147-157.

Matusiak, L., Bieniek, A., & Szepietowski, J. C. (2009). Increased serum tumour necrosis factor-α in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-α agents? . Acta Derm Venereol, 89(6), 601-603.

Riis, P. T., Soeby, K., Saunte, D. M., & Jemec, G. B. (2015). Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients. Arch Dermatol Res, 307(10), 885-889.

van der Zee, H. H., de Ruiter, L., van den Broecke, D. G., Dik, W. A., Laman, J. D., & Prens, E. P. (2011b). Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol., 164(6), 1292-1298.

Roussomoustakaki, M., Dimoulios, P., Chatzicostas, C., Kritikos, H. D., Romanos, J., Panayiotides, J. G., & Kouroumalis, E. A. (2003). Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol, 38(10), 1000-1004.

Van der Zee, H. H., de Winter, K., van der Woude, C. J., & Prens, E. P. (2014). The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease. Br J Dermatol, 171(3), 673-675.

Yadav, S., Singh, S., Edakkanambeth Varayil, J., Harmsen, W. S., Zinsmeister, A. R., Tremaine, W. J., Loftus, E. V., Jr. (2016). Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol, 14(1), 65-70.

Richette, P., Molto, A., Viguier, M., Dawidowicz, K., Hayem, G., Nassif, A., . . . Bachelez, H. (2014). Hidradenitis suppurativa associated with spondyloarthritis -- results from a multicenter national prospective study. J Rheumatol, 41(3), 490-494.

Rosner, I. A., Richter, D. E., Huettner, T. L., Kuffner, G. H., Wisnieski, J. J., & Burg, C. G. (1982). Spondyloarthropathy Associated with Hidradenitis Suppurativa and Acne Conglobata. Annals of Internal Medicine, 97, 520-525.

Fimmel, S., & Zouboulis, C. C. (2010). Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol, 2(1), 9-16.

Dessinioti, C., Katsambas, A., & Antoniou, C. (2014). Hidradenitis suppurrativa (acne inversa) as a systemic disease. Clin Dermatol, 32(3), 397-408.

Hsiao, J. L., Antaya, R. J., Berger, T., Maurer, T., Shinkai, K., & Leslie, K. S. (2010). Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol, 146(11), 1265-1270.

Sahin, M. T., Ozturkcan, S., Turel-Ermertcan, A., Yurtman-Havlucu, D., & Bilac, C. (2007). Behçet’s disease associated with hidradenitis suppurativa. J Eur Acad Dermatol Venereol, 21(3), 428-429.

Nguyen, M. T., Borchers, A., Selmi, C., Naguwa, S. M., Cheema, G., & Gershwin, M. E. (2012). The SAPHO syndrome. Semin Arthritis Rheum, 42(3), 254-265.

Choudhary, S. V., Jain, D., Agrawal, P., & Singh, A. (2013). Dowling-Degos disease and hidradenitis suppurativa: Co occurrence or association? Indian Dermatol Online J, 4(3), 191-194.

Montgomery, J. R., White, T. W., Martin, B. L., Turner, M. L., & Holland, S. M. (2004). A novel connexin 26 gene mutation associated with features of the keratitis-ichthyosis-deafness syndrome and the follicular occlusion triad. J Am Acad Dermatol, 51(3), 377-382.

Todd, P., Garioch, J., Rademaker, M., Susskind, W., Gemell, C., & Thomson, J. (1990). Pachyonychia congenita complicated by hidradenitis suppurativa: a family study. Br J Dermatol, 123(5), 663-666.

Lavogiez, C., Delaporte, E., Darras-Vercambre, S., Martin De Lassalle, E., Castillo, C., Mirabel, X., . . . Mortier, L. (2010). Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology, 220(2), 147-153.

Lapins, J., Weimin, Y., Nyren, O., & Emtestam, L. (2001). Incidence of Cancer Among Patients With Hidradenitis Suppurativa. Arch Dermatol, 137(6), 730-734.

Karagiannidis, I., Nikolakis, G., & Zouboulis, C. C. (2016). Endocrinologic Aspects of Hidradenitis Suppurativa. Dermatol Clin, 34(1), 45-49.

Harrison, B. J., Kumar, S., Read, G. F., Edwards, C. A., Scalon, M. F., & Hughes, L. E. (1985). Hidradenitis suppurativa: evidence for an endocrine abnormality. 72, 1002-1004.

Buimer, M. G., Wobbes, T., Klinkenbijl, J., Reijnen, M., & Blokx, W. (2015). Immunohistochemical Analysis of Steroid Hormone Receptors in Hidradenitis Suppurative. Am J Dermatopathol, 37(2), 129-132.

Barth, J. H., Layton, A. M., & Cunliffe, vW. J. (1996). Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. British Journal of Dermatology, 134, 1057-1059.

Onderdijk, A. J., van der Zee, H. H., Esmann, S., Lophaven, S., Dufour, D. N., Jemec, G. B., & Boer, J. (2013). Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol, 27(4), 473-478.

Von der werth, J. M., & Jemec, G. B. (2001). Morbidity in patients with hidradenitis suppurativa. British Journal of Dermatology, 144, 809-813.

Wolkenstein, P., Loundou, A., Barrau, K., Auquier, P., Revuz, J., & Quality of Life Group of the French Society of, D. (2007). Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol, 56(4), 621-623.

Matusiak, L., Bieniek, A., & Szepietowski, J. C. (2010). Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol, 62(4), 706-707.

Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62(6), 593-602.

Shavit, E., Dreiher, J., Freud, T., Halevy, S., Vinker, S., & Cohen, A. D. (2015). Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol, 29(2), 371-376.

Kimball, A. B., Kerdel, F., Adams, D., Mrowietz, U., Gelfand, J. M., Gniadecki, R., Jemec, G. B. (2012). Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med, 157(12), 846-855.

DOI: http://dx.doi.org/10.18103/imr.v0i6.131

Refbacks

There are currently no refbacks.

Search within